Kenneth Nilsson
Professor emeritus at Department of Immunology, Genetics and Pathology; Research programme: Cancer Precision Medicine; Research group Helena Jernberg Wiklund
- Mobile phone:
- +46 70 832 16 44
- E-mail:
- kenneth-n.nilsson@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 UPPSALA
Publications
Recent publications
-
Part of Oncotarget, p. 103731-103743, 2017
- DOI for The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomain
- Download full text (pdf) of The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomain
-
Part of Oncotarget, p. 10213-10224, 2017
- DOI for EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
- Download full text (pdf) of EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
-
The Transcriptomic and Proteomic Landscapes of Bone Marrow and Secondary Lymphoid Tissues
Part of PLOS ONE, 2014
- DOI for The Transcriptomic and Proteomic Landscapes of Bone Marrow and Secondary Lymphoid Tissues
- Download full text (pdf) of The Transcriptomic and Proteomic Landscapes of Bone Marrow and Secondary Lymphoid Tissues
-
Part of Blood, 2014
-
Part of Leukemia and Lymphoma, p. 1769-1779, 2013
All publications
Articles in journal
-
Part of Oncotarget, p. 103731-103743, 2017
- DOI for The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomain
- Download full text (pdf) of The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomain
-
Part of Oncotarget, p. 10213-10224, 2017
- DOI for EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
- Download full text (pdf) of EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
-
The Transcriptomic and Proteomic Landscapes of Bone Marrow and Secondary Lymphoid Tissues
Part of PLOS ONE, 2014
- DOI for The Transcriptomic and Proteomic Landscapes of Bone Marrow and Secondary Lymphoid Tissues
- Download full text (pdf) of The Transcriptomic and Proteomic Landscapes of Bone Marrow and Secondary Lymphoid Tissues
-
Part of Blood, 2014
-
Part of Leukemia and Lymphoma, p. 1769-1779, 2013
-
Part of BMC Cancer, p. 318, 2012
- DOI for Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
- Download full text (pdf) of Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
-
Tumor-Initiating Cells in Childhood Neuroblastoma: Letter
Part of Cancer Research, p. 821-822, 2012
-
The novel NF-kappa B inhibitor IMD-0354 induces apoptosis in chronic lymphocytic leukemia
Part of Blood Cancer Journal, 2011
-
Large-Scale Protein Profiling in Human Cell Lines Using Antibody-Based Proteomics
Part of Journal of Proteome Research, p. 4066-4075, 2011
-
Polycomb target genes are silenced in multiple myeloma
Part of PLOS ONE, 2010
- DOI for Polycomb target genes are silenced in multiple myeloma
- Download full text (pdf) of Polycomb target genes are silenced in multiple myeloma
-
Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma
Part of Experimental Hematology, p. 1673-1681, 2008
-
Positive histone marks are associated with active transcription from a methylated ICSBP/IRF8 gene
Part of Gene, p. 259-267, 2008
-
Part of Molecular Immunology, p. 615-624, 2007
-
Part of International Journal of Cancer, p. 1857-1861, 2007
-
Part of Scandinavian Journal of Immunology, p. 271-279, 2006
-
Part of Blood, p. 669-78, 2006
-
Part of Blood, p. 655-60, 2006
-
Part of Blood, p. 1346-1354, 2005
-
Part of Leukemia, p. 871-873, 2005
-
Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone.
Part of Blood, p. 3138-47, 2004
-
Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines.
Part of Anticancer Drugs, p. 63-70, 2004
-
Part of Leukemia Res, p. 1043-1051, 2004
-
Differentiation-associated redox-regulation in human B cell lines from stemcell/pro-B to plasma cell
Part of Immunology Letters, p. 83-89, 2004
-
VH gene mutation status and cellular drug resistance in chronic lymphocytic leukemia
Part of Eur J Haematol, p. 407-411, 2004
-
Part of Anti-Cancer Drugs, p. 45-54, 2004
-
Part of Thrombosis and Haemostasis, p. 930-9, 2003
-
Part of Int J Cancer, p. 197-201, 2003
-
Part of Blood, p. 254, 2003
-
Part of Eur J Haematol, p. 76-89, 2002
-
Part of Blood, p. 2199, 2002
-
Part of Leukemia, p. 217-227, 2001
-
The role of RAR and RXR activation in retinoid-induced tissue factor suppression
Part of Leukemia, p. 1105-11, 2000
-
Thioredoxin prolongs survival of B-type chronic lymphocytic leukemia cells
Part of Blood, p. 1420-1426, 2000
-
Part of Biometals, p. 101-11, 2000
-
Part of Blood, p. 2870, 2000
-
Part of European Journal of Haematology, p. 112-119, 1999
-
Part of Scand J Immunol, p. 363-70, 1999
-
Part of Blood, p. 1724, 1999
-
Part of Blood, p. 2914, 1998
-
Part of Journal of Biological Chemistry, p. 9443-9, 1997
- DOI for Retinoic acid receptor/retinoid X receptor heterodimers can be activated through both subunits providing a basis for synergistic transactivation and cellular differentiation
- Download full text (pdf) of Retinoic acid receptor/retinoid X receptor heterodimers can be activated through both subunits providing a basis for synergistic transactivation and cellular differentiation
-
Part of Leukemia, p. 142-4, 1997
-
Myeloperoxidase mediates cell adhesion via the alpha M beta 2 integrin (Mac-1, CD11b/CD18)
Part of Journal of Cell Science, p. 1133-1139, 1997
-
Tissue factor expression in human monocytic cell lines
Part of Thrombosis Research, p. 215-28, 1997
-
Part of Leukemia, p. 1298-304, 1997
-
Part of Br J Haematol, p. 126-33, 1997
-
Part of Br J Haematol, p. 126, 1997
-
Part of Scand J Immunol, p. 706-14, 1997
-
Part of Cell growth & differentiation, p. 1239-49, 1996
-
Characterization of a human basophil-like cell line (LAMA-84)
Part of Scand. J. Immunol., p. 54-61, 1996
-
Part of Immunology, p. 308-314, 1996
-
Part of Int. J. Cancer, p. 451, 1996
-
Insulin-like growth factor I is a growth- and survival factor in human multiple myeloma cell lines.
Part of Blood, p. 2250, 1996
-
Part of Leukemia, p. 2034-41, 1995
Articles, review/survey
-
Part of Upsala Journal of Medical Sciences, p. 166-177, 2012
-
Control of Apoptosis in Human Multiple Myeloma by Insulin-like Growth Factor I (IGF-I)
Part of Advances in Cancer Research, p. 139-165, 2007
Chapters in book
-
Plasma Cell and Myeloma Cell Lines
Part of Human Cell Culture, Kluwer Academic Publishers, 2000
-
Stat1 involvement in retinoic acid induced differentiation of myeloid cells
Part of Molecular mechanisms of signal transduction, p. 211, IOS press, Amsterdam, The Netherlands, 2000
-
Part of Transplantation Biology, p. 241, Lippincott-Raven, 1996
Conference papers
-
Cytokine induced inhibition of Myc activity in monocytic cells
Part of C-myc in B-cell neoplasia, p. 191, 1997
Manuscripts (preprints)
Other
-
Toward a rational combinaTORial therapy for multiple myeloma
Part of Blood, p. 3845-3846, 2004
-
The control of proliferation, survival and apoptosis in human multiple myeloma cells in vitro
Part of MECHANISMS OF B CELL NEOPLASIA 1998, p. 325-333, 1999